World Journal of Hepatology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Number of total visits: 2801828

Number of visits today: 86

Number of downloads: 2055768

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Cacciola I, Russo G, Filomia R, Pitrone C, Caccamo G, Giandalia A, Alibrandi A, Stella Franzè M, Porcari S, Maimone S, Saitta C, Squadrito G, Raimondo G. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. Liver Int 2021;41:2059-67. [PMID: 33894103 DOI: 10.1111/liv.14905] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]

For:

Cacciola I, Russo G, Filomia R, Pitrone C, Caccamo G, Giandalia A, Alibrandi A, Stella Franzè M, Porcari S, Maimone S, Saitta C, Squadrito G, Raimondo G. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. Liver Int 2021;41:2059-67. [PMID: 33894103 DOI: 10.1111/liv.14905] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]

Number	Citing Articles
1	Hung HY, Lai HH, Lin HC, Chen CY. The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis. Ann Med 2023;55:463-79. [PMID: 36655629 DOI: 10.1080/07853890.2023.2168745] [Reference Citation Analysis]
2	Barré T, Carrat F, Ramier C, Fontaine H, Di Beo V, Bureau M, Dorival C, Larrey D, Delarocque-astagneau E, Mathurin P, Marcellin F, Petrov-sanchez V, Cagnot C, Carrieri P, Pol S, Protopopescu C, Alric L, Pomes C, Zoulim F, Maynard M, Bai R, Hucault L, Bailly F, Raffi F, Billaud E, Boutoille D, Lefebvre M, André-garnier E, Cales P, Hubert I, Lannes A, Lunel F, Boursier J, Asselah T, Boyer N, Giuily N, Castelnau C, Scoazec G, Pol S, Fontaine H, Rousseaud E, Vallet-pichard A, Sogni P, de Ledinghen V, Foucher J, Hiriart J, M’bouyou J, Irlès-depé M, Bourlière M, Ahmed SNS, Oules V, Tran A, Anty R, Gelsi E, Truchi R, Thabut D, Hammeche S, Moussali J, Causse X, De Dieuleveult B, Ouarani B, Labarrière D, Ganne N, Grando-lemaire V, Nahon P, Brulé S, Ulker B, Guyader D, Jezequel C, Brener A, Laligant A, Rabot A, Renard I, Habersetzer F, Baumert TF, Doffoel M, Mutter C, Simo-noumbissie P, Razi E, Bronowicki J, Barraud H, Bensenane M, Nani A, Hassani-nani S, Bernard M, Pageaux G, Larrey D, Meszaros M, Metivier S, Bureau C, Morales T, Peron JM, Robic MA, Decaens T, Faure M, Froissart B, Hilleret M, Zarski J, Riachi G, Goria O, Paris F, Montialoux H, Leroy V, Amaddeo G, Varaut A, Simoes M, Amzal R, Chazouillières O, Andreani T, Angoulevant B, Chevance A, Serfaty L, Samuel D, Antonini T, Coilly A, Duclos-vallée J, Tateo M, Abergel A, Reymond M, Brigitte C, Benjamin B, Muti L, Geist C, Conroy G, Riffault R, Rosa I, Barrault C, Costes L, Hagège H, Loustaud-ratti V, Carrier P, Debette-gratien M, Mathurin P, Lassailly G, Lemaitre E, Canva V, Dharancy S, Louvet A, Minello A, Latournerie M, Bardou M, Mouillot T, D’alteroche L, Barbereau D, Nicolas C, Elkrief L, Jaillais A, Gournay J, Chevalier C, Archambeaud I, Habes S, Portal I, Gelu-simeon M, Saillard E, Lafrance M, Catherine L, Carrat F, Chau F, Dorival C, Goderel I, Lusivika-nzinga C, Bellance M, Bellet J, Monfalet P, Chane-teng J, Bijaoui S, Pannetier G, Téoulé F, Nicol J, Sebal F, Bekhti R, Cagnot C, Boston A, Nailler L, Le Meut G, Diallo A, Petrov-sanchez V, Bourlière M, Boursier J, Carrat F, Carrieri P, Delarocque-astagneau E, De Ledinghen V, Dorival C, Fontaine H, Fourati S, Housset C, Larrey D, Nahon P, Pageaux G, Petrov-sanchez V, Pol S, Bruyand M, Wittkop L, Zoulim F, Zucman-rossi J, L’hennaff M, Sizorn M, Cagnot C, the ANRS/AFEF Hepather study group. Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. J Cannabis Res 2022;4:31. [DOI: 10.1186/s42238-022-00138-9] [Reference Citation Analysis]
3	Franzè MS, Filomia R, Caccamo G, Pitrone C, Alibrandi A, Saitta C, Caspanello AR, Asero C, Arcadi V, Raimondo G, Cacciola I. Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance. J Pers Med 2022;12. [PMID: 36579534 DOI: 10.3390/jpm12111794] [Reference Citation Analysis]
4	Dalbeni A, Villani R, Bevilacqua M, Sacco F, Faccincani D, Cattazzo F, Cavallone F, Mantovani A, Ceruti V, Ieluzzi D, Paon V, Mantovani A, Serviddio G, Sacerdoti D. Effects of direct-acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real-life Italian experience. J Dig Dis 2022;23:324-30. [PMID: 35700113 DOI: 10.1111/1751-2980.13103] [Reference Citation Analysis]
5	Ciardullo S, Mantovani A, Ciaccio A, Carbone M, Invernizzi P, Perseghin G. Hepatitis C virus infection and diabetes: A complex bidirectional relationship. Diabetes Research and Clinical Practice 2022;187:109870. [DOI: 10.1016/j.diabres.2022.109870] [Reference Citation Analysis]